ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

ACTON, Mass., March 19, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...

ACTON, Mass., March 18, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, ...

Largest, longest, and most racially diverse study of automated insulin delivery (AID) conducted in people with type 2 diabetes to date Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the ...

Insulet Enrolls First Patients in Clinical Trial for its Omnipod® Artificial Pancreas System Study Brings Insulet Another Step Closer to Providing its Omnipod® Horizon ™ Hybrid Closed Loop System to ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic ...

Insulet Corporation PODD recently announced positive results from the first pivotal study for the Omnipod 5 Automated Insulin Delivery System. The finding of the study suggests that Omnipod 5 ...

Insulet Corporation PODD recently announced positive results from the first pivotal study for the Omnipod 5 Automated Insulin Delivery System. The finding of the study suggests that Omnipod 5 ...